Haloperidol

Haloperidol hydrochloride, a potent dopamine D2 receptor antagonist, is an effective antipsychotic agent.

Haloperidol D4' is deuterium-labeled haloperidol. Haloperidol is a dopamine D2 receptor antagonist.

Haloperidol D4 is deuterium-labeled haloperidol.

Haloperidol is an effective dopamine D2 receptor antagonist that can be used to induce models of tardive dyskinesia and Parkinson’s disease.

HPTP is a monoaminergic neurotoxin related to MPTP. It is the dehydration product of haloperidol. The agent is specifically a dopaminergic and serotonergic neurotoxin. HPTP is a prodrug of HPP+, which mediates its monoaminergic neurotoxicity, HPTP can be utilized for building neurotoxic or immuno-deficient model for research related to neuroscience.

Haloperidol decanoate (KD 16) is a typical antipsychotic agent utilized as maintenance treatment for schizophrenia and mood disorders formulated as an ester for intramuscular injection.

Haloperidol lactate is a potent antipsychotic. haloperidol lactate has potential for studies in psychiatric disorders. haloperidol lactate can be used in acute and chronic schizophrenia and polyarousal syndrome.

Reduced Haloperidol (Standard) is a reference standard for research and analysis in studies involving Reduced Haloperidol. Reduced haloperidol is an active metabolite of haloperidol . It is formed via reduction of haloperidol by ketone reductase. Reduced haloperidol inhibits radioligand binding to sigma-1 and dopamine D2 receptors (Kis = 1.4 and 31 nM, respectively) and stimulates brain-derived neurotrophic factor (BDNF) secretion from CCF-SSTG1 and U87MG astrocytic glial cells. It also inhibits norepinephrine, dopamine, and serotonin (5-HT) reuptake (Kis = 21, 25, and 33 μM, respectively, in COS-7 cells expressing the human transporters). Reduced haloperidol (0.5 mg/kg) increases latency to paw withdrawal in mouse models of capsaicin- but not force-induced mechanical hypersensitivity.

Reduced haloperidol is an active metabolite of haloperidol . It is formed via reduction of haloperidol by ketone reductase. Reduced haloperidol inhibits radioligand binding to sigma-1 and dopamine D2 receptors (Kis = 1.4 and 31 nM, respectively) and stimulates brain-derived neurotrophic factor (BDNF) secretion from CCF-SSTG1 and U87MG astrocytic glial cells. It also inhibits norepinephrine, dopamine, and serotonin (5-HT) reuptake (Kis = 21, 25, and 33 μM, respectively, in COS-7 cells expressing the human transporters). Reduced haloperidol (0.5 mg/kg) increases latency to paw withdrawal in mouse models of capsaicin- but not force-induced mechanical hypersensitivity.

Reduced Haloperidol-d4 is a deuterated compound of Reduced Haloperidol. Reduced Haloperidol has a CAS number of 34104-67-1.

Haloperidol (Standard) is a reference standard for research and analysis in studies involving Haloperidol. Haloperidol is an effective dopamine D2 receptor antagonist that can be used to induce models of tardive dyskinesia and Parkinson’s disease.

Haloperidol-d4 TFA is a deuterated compound of Haloperidol TFA.

Palmitoyl glutamic acid (N-Palmitoyl-L-glutamic acid) is an acyl amino acid that inhibits aortic constriction and counteracts haloperidol-induced oral motility disorders.

Spiperone (Spiropitan) is a spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.

Raseglurant (ADX-10059) is an mGlu5 negative allosteric modulator. It effectively counters migraines and alleviates haloperidol-induced catalepsy in mice.

Carpipramine (free base) is an atypical antipsychotic compound utilized in France and Japan to treat schizophrenia and anxiety. In addition to its neuroinhibitory and anxiolytic effects, it also possesses hypnotic properties. Structurally, carpipramine resembles tricyclic compounds like imipramine and is related to butyrophenones such as haloperidol.

Loperamide is a opioid-receptor selective agonist. Its chemical structure is similar to that of haloperidol and pethidine, and it is suitable for acute diarrhea as well as chronic diarrhea caused by various etiology.

A-86929 is a potent and selective dopamine D1 receptor agonist with a pKi of 7.3. It significantly induces rotational behavior in a 6-OHDA-induced unilateral nigral lesion rat model and improves motor function in an MPTP-induced Parkinson's disease marmoset model. Furthermore, A-86929 shows potential value in reducing cocaine-induced craving behavior in rats and reversing Haloperidol-induced cognitive deficits in rhesus monkeys. The compound is useful for researching neurological disorders.

VU0477886 is a potent mGlu4 positive allosteric modulator (PAM) with robust efficacy in a standard preclinical Parkinson's disease model, haloperidol-induced catalepsy (HIC).

Acetyl β-endorphin (1-26) is a neuropeptide found in rat hippocampus, brain stem, and pituitary. It is also present in the human hypothalamus, where it comprises approximately 4.9% of total β-endorphin peptides. Acetyl β-endorphin (1-26) is produced through posttranslational processing of β-endorphin and is processed similarly in rat and human hypothalamus. Levels of acetyl β-endorphin (1-26) increase in the rat pars intermedia and brain stem following chronic administration of haloperidol .

Antibacterial agent 67 significantly inhibited the activity of succinate dehydrogenase with an IC50 value of 0.03 μM and showed significantly higher enzymatic inhibitory activity against succinate dehydrogenase than haloperidol (IC50= 4.40 μM).

Ro 04-5595 is a selective antagonist of NMDA receptors NR2B subunits. Ro 04-5595 had an EC 50 of 186 ± 32 nmol/L. Ro 04-5595 was predicted to bind the EVT-101 binding site, not the ifenprodil-binding site. Specific binding, defined with a new NR2B-specific antagonist Ro 04-5595 at 10 microM was fully inhibited by several compounds with the following rank order of affinities--Ro 25-6981 > CP-101,606 > Ro 04-5595 = ifenprodil >> eliprodil > haloperidol > spermine > spermidine > MgCl2 > CaCl2--and partially inhibited by competitive glutamate recognition site antagonists. Complementary high-resolution autoradiographic images using [3H]Ro04-5595 demonstrated strong binding in NR2B receptor-rich regions and low binding in cerebellum where NR2B concentration is low.

(S)-(-)-MRJF22, a haloperidol metabolite II valproate ester, demonstrates potent antimigratory effects in both endothelial and tumor cells, and is considered a promising multifunctional agent in the treatment of uveal melanoma [1].